瑞舒伐他汀对心力衰竭大鼠心功能的改善作用及其机制
|
摘要
目的研究瑞舒伐他汀对心力衰竭大鼠心功能的改善作用及其机制。方法将39只SD大鼠随机分为对照组,模型组及实验组,各13只。模型组及实验组予以皮下注射异丙肾上腺素5 mg·kg~(-1),qd,共7 d,建立心力衰竭大鼠模型,对照组予以皮下注射等量0. 9%NaCl。建模成功后,实验组予以灌胃瑞舒伐他汀5 mg·kg~(-1),模型组及对照组则予以灌胃等量0. 9%Na Cl,qd,共14 d。用超声检测及酶联免疫吸附实验(ELISA)检测大鼠心功能指标;用蛋白免疫印迹法检测大鼠心肌组织有丝分裂原激活的蛋白激酶(MAPK)通路相关蛋白表达。结果对照组,模型组和实验组左心室射血分数(LVEF)分别为(81. 23±5. 46)%,(53. 47±5. 18)%,(59. 09±5. 33)%,血清脑钠肽分别为(123. 11±20. 15),(157. 46±19. 87),(141. 01±19. 08) pg·m L~(-1),肌钙蛋白Ⅰ分别为(33. 57±9. 68),(42. 52±9. 71),(33. 45±9. 56) pg·m L~(-1)。对照组,模型组及实验组大鼠心肌组织p38-MAPK相对表达量分别为0. 56±0. 11,1. 13±0. 05,0. 78±0. 04; P-p44ERK相对表达量分别为0. 26±0. 05,0. 43±0. 04,0. 36±0. 05; P-p42ERK相对表达量分别为1. 56±0. 21,0. 91±0. 04,1. 03±0. 03; P-p54JNK相对表达量分别为0. 19±0. 05,0. 39±0. 02,0. 21±0. 03; P-p46JNK相对表达量分别为0. 75±0. 11,1. 02±0. 01,0. 82±0. 02。模型组与实验组比较,差异均有统计学意义(均P <0. 05)。结论瑞舒伐他汀可改善心力衰竭大鼠心功能,其作用机制与其有效调控MAPK通路相关蛋白表达相关。
Objective To explore the improving effect of rosuvastatin on the cardiac function of heart failure rats,and analyse the related mechanism. Methods A total of 39 SD rats were randomly assigned to control group,model group and experimental group,each group with 13 rats.The model group and experimental group received subcutaneous injection of 5 mg·kg~(-1) of isoprenaline once daily for 7 d to induce heart failure rat model,while the control group was given subcutaneous injection of0. 9% NaCl. After the heart failure rat model was established,the experimental group received oral administration of 5 mg·kg~(-1) of rosuvastatin once daily,while the model group and control group received 0. 9%NaCl. Each group were given treatment for 2 weeks. Ultrasound technique and enzyme linked immunosorbent assay( ELISA) were used for the measurement of cardiac function indexes; the Western Blot( WB) was used to detect the expression of rats myocardium mitogen-activated protein kinase( MAPK)-associated protein. Results Of the control group,model group and experimental group,the left ventricular ejection fraction( LVEF) were( 81. 23 ± 5. 46) %,( 53. 47 ± 5. 18) %,( 59. 09 ± 5. 33) %, respectively; the levels of serum brain natriuretic peptide were( 123. 11 ± 20. 15),( 157. 46 ± 19. 87),( 141. 01 ± 19. 08) pg · m L~(-1), respectively; cardiac troponin I were( 33. 57 ± 9. 68),( 42. 52 ± 9. 71),( 33. 45 ± 9. 56) pg·m L~(-1),respectively; the relative expression of p38-MAPK in myocardium were0. 56 ± 0. 11,1. 13 ± 0. 05,0. 78 ± 0. 04,respectively; the relative expression of P-p44 ERK were 0. 26 ± 0. 05,0. 43 ± 0. 04,0. 36 ± 0. 05,respectively; the relative expression of P-p42 ERK were 1. 56 ± 0. 21,0. 91 ± 0. 04,1. 03 ± 0. 03,respectively; the relative expression of P-p54 JNK were 0. 19 ± 0. 05,0. 39 ± 0. 02,0. 21 ± 0. 03,respectively; the relative expression of P-p46 JNK were 0. 75 ± 0. 11,1. 02 ± 0. 01,0. 82 ± 0. 02,respectively. There were significant difference between the model group and the control group( P < 0. 05). Conclusion Rosuvastatin can improve cardiac function of the heart failure rats,and the regulation of MAPK-protein expression might be involved in the process.
Objective To explore the improving effect of rosuvastatin on the cardiac function of heart failure rats,and analyse the related mechanism. Methods A total of 39 SD rats were randomly assigned to control group,model group and experimental group,each group with 13 rats.The model group and experimental group received subcutaneous injection of 5 mg·kg~(-1) of isoprenaline once daily for 7 d to induce heart failure rat model,while the control group was given subcutaneous injection of0. 9% NaCl. After the heart failure rat model was established,the experimental group received oral administration of 5 mg·kg~(-1) of rosuvastatin once daily,while the model group and control group received 0. 9%NaCl. Each group were given treatment for 2 weeks. Ultrasound technique and enzyme linked immunosorbent assay( ELISA) were used for the measurement of cardiac function indexes; the Western Blot( WB) was used to detect the expression of rats myocardium mitogen-activated protein kinase( MAPK)-associated protein. Results Of the control group,model group and experimental group,the left ventricular ejection fraction( LVEF) were( 81. 23 ± 5. 46) %,( 53. 47 ± 5. 18) %,( 59. 09 ± 5. 33) %, respectively; the levels of serum brain natriuretic peptide were( 123. 11 ± 20. 15),( 157. 46 ± 19. 87),( 141. 01 ± 19. 08) pg · m L~(-1), respectively; cardiac troponin I were( 33. 57 ± 9. 68),( 42. 52 ± 9. 71),( 33. 45 ± 9. 56) pg·m L~(-1),respectively; the relative expression of p38-MAPK in myocardium were0. 56 ± 0. 11,1. 13 ± 0. 05,0. 78 ± 0. 04,respectively; the relative expression of P-p44 ERK were 0. 26 ± 0. 05,0. 43 ± 0. 04,0. 36 ± 0. 05,respectively; the relative expression of P-p42 ERK were 1. 56 ± 0. 21,0. 91 ± 0. 04,1. 03 ± 0. 03,respectively; the relative expression of P-p54 JNK were 0. 19 ± 0. 05,0. 39 ± 0. 02,0. 21 ± 0. 03,respectively; the relative expression of P-p46 JNK were 0. 75 ± 0. 11,1. 02 ± 0. 01,0. 82 ± 0. 02,respectively. There were significant difference between the model group and the control group( P < 0. 05). Conclusion Rosuvastatin can improve cardiac function of the heart failure rats,and the regulation of MAPK-protein expression might be involved in the process.
引文
[1]宋秀敏.观察慢性心力衰竭患者经他汀类药物治疗的疗效[J].中西医结合心血管病电子杂志,2015,3(6):99-100.
[2]XIE R,CUI W,WANG Y.The effects of rosuvastatin on cardiac function and serum MPO,MMP-9 in patients with chronic heart failure[J].Am J Cardiol,2013,111(7):75.
[3]高占义,魏月娟,王彦敏,等.自拟强心汤对心梗后心力衰竭大鼠心肌舒缩功能的实验研究[J].世界中医药,2016,11(11):2363-2366.
[4]邹燕.真武汤对心力衰竭大鼠心室重构及心功能的影响[D].沈阳:辽宁中医药大学,2016.
[5]徐清斌,熊爱琴,徐烨华,等.瑞舒伐他汀通过NO/e NOS信号通路改善慢性心力衰竭大鼠的心功能[J].华中科技大学学报(医学版),2015,44(2):160-164.
[6]陈广辉.瑞舒伐他汀对慢性心力衰竭患者心功能的影响[J].中国医药导报,2013,10(30):101-103.
[7]赵金红.p38MAPK信号通路与心脏重构关系的研究进展[J].医学综述,2013,19(13):2312-2314.
[2]XIE R,CUI W,WANG Y.The effects of rosuvastatin on cardiac function and serum MPO,MMP-9 in patients with chronic heart failure[J].Am J Cardiol,2013,111(7):75.
[3]高占义,魏月娟,王彦敏,等.自拟强心汤对心梗后心力衰竭大鼠心肌舒缩功能的实验研究[J].世界中医药,2016,11(11):2363-2366.
[4]邹燕.真武汤对心力衰竭大鼠心室重构及心功能的影响[D].沈阳:辽宁中医药大学,2016.
[5]徐清斌,熊爱琴,徐烨华,等.瑞舒伐他汀通过NO/e NOS信号通路改善慢性心力衰竭大鼠的心功能[J].华中科技大学学报(医学版),2015,44(2):160-164.
[6]陈广辉.瑞舒伐他汀对慢性心力衰竭患者心功能的影响[J].中国医药导报,2013,10(30):101-103.
[7]赵金红.p38MAPK信号通路与心脏重构关系的研究进展[J].医学综述,2013,19(13):2312-2314.